Adebrelimab and Fruquintinib Combined With Paclitaxel/Albumin Paclitaxel for Advanced Gastric Cancer After PD-1 Antibody Failed

NCT ID: NCT06102759

Last Updated: 2023-10-26

Basic Information

• Recruitment Status: RECRUITING
• Total Enrollment: 30 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2023-11-10
• Study Completion Date: 2026-10-10

Brief Summary

This is a prospective, single-center, open, single-arm clinical study to observe and evaluate the efficacy and safety of Fruquintinib and Adebrelimab combined with paclitaxel/albumin paclitaxel for second-line treatment of advanced gastric cancer.

Detailed Description

Since the first-line ICIs application of gastric cancer is mainly PD-1 antibody, this study intends to screen first-line patients exposed to PD-1 antibody and with long survival (PFS longer than 9 months) to receive second-line PD-L1 antibody for re-challenge and combine with Fruquintinib and paclitaxel to explore whether it can further increase the effect of second-line treatment.

Conditions

Gastric Cancer

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

Adebrelimab, Fruquintinib combined with paclitaxel

Fruquintinib 4mg d1-14, q3w Paclitaxel 150mg/m2, d1, q3w / Albumin paclitaxel 125mg/m2, d1, d8, q3w PD-L1 antibody (Adebrelimab) 20 mg/kg, d1, q3w

Adebrelimab，Fruquintinib

Intervention Type: DRUG

Adebrelimab，Fruquintinib combined with chemotherapy

Interventions

Adebrelimab，Fruquintinib

Adebrelimab，Fruquintinib combined with chemotherapy

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Age ≥18 years old.

2. The ECOG score is 0-1 and does not deteriorate within 7 days.

3. Patients with histologically confirmed, metastatic, or unresectable locally advanced gastric cancer or GEJ adenocarcinoma.

4. Previously received one systemic chemotherapy regimen for this cancer and progressed; Or have received adjuvant chemotherapy, but have disease progression or recurrence within 6 months after the end of treatment.

5. First-line exposure to PD-1 antibodies and first-line treatment of PFS greater than 9 months.

6. Measurable lesions that meet RECIST 1.1 criteria.

7. Have adequate organ and bone marrow function, laboratory tests meet the following requirements:

1. HGB≥90g/L;

2. NEUT≥1.5×10^9/L;

3. PLT ≥80×10^9/L;

4. TBIL≤1.5 times upper limit of normal value (ULN);

5. ALT and AST≤2.5 x ULN; In liver metastasis, ALT and AST≤5×ULN;

6. Endogenous creatinine clearance ≥50ml/min (Cockcroft-Gault formula);

7. Urinary protein < (++), or 24-hour urinary protein volume < 1.0 g.

8. Normal coagulation function, no active bleeding

1. International standardized ratio INR≤1.5;

2. Partial thromboplastin time APTT≤1.5 ULN.

9. Women of childbearing age must undergo a negative pregnancy test (serum or urine) within 14 days prior to enrollment and voluntarily use an appropriate method of contraception during the observation period and within 8 weeks after the last dose of the study drug; For men, they should be surgically sterilized or consent to an appropriate method of contraception during the observation period and for 8 weeks after the last administration of the study drug.

10. Expected survival ≥3 months.

11. Patients voluntarily joined the study and signed an informed consent form (ICF).

12. It is expected that the compliance is good, and the efficacy and adverse reactions can be followed up according to the protocol requirements.

Exclusion Criteria

1. Previous treatment with VEGFR inhibitors;

2. Previously received paclitaxel therapy (except for those who received paclitaxel therapy in neoadjuvant or adjuvant therapy, and the treatment ended more than 6 months after the disease progression);

3. Receive live vaccine within 4 weeks prior to enrollment or possibly during the study period;

4. Had active autoimmune disease or history of autoimmune disease within 4 weeks prior to enrollment;

5. Previously received allogeneic bone marrow transplantation or organ transplantation;

6. Hypertension that could not be controlled by drugs before enrollment was defined as: systolic blood pressure ≥150 mmHg and/or diastolic blood pressure ≥90 mmHg;

7. Had any disease or condition affecting drug absorption before enrollment, or the patient could not take drugs orally;

8. Gastrointestinal diseases such as active ulcer of stomach and duodenum, ulcerative colitis, or active bleeding of unexcised tumors, or other conditions that may cause gastrointestinal bleeding or perforation as determined by researchers before enrollment;

9. Patients with evidence or history of significant bleeding tendency within 3 months prior to enrollment (bleeding within 3 months > 30 mL, hematemesis, stool, stool blood), hemoptysis, or thromboembolic events (including stroke events and/or transient ischemic attacks) within 12 months;

10. Clinically significant cardiovascular disease, including but not limited to acute myocardial infarction, severe/unstable angina pectoris, or coronary artery bypass grafting within 6 months prior to enrollment; New York Heart Association (NYHA) Grades for Congestive Heart Failure > Level 2; Ventricular arrhythmias requiring medical treatment; LVEF (Left ventricular Ejection Fraction) < 50%;

11. Active or uncontrolled severe infection (≥CTCAE v5.0 grade 2 infection);

12. Known human immunodeficiency virus (HIV) infection. Known history of clinically significant liver disease, including viral hepatitis [Known hepatitis B virus (HBV) carriers must rule out active HBV infection, i.e., positive HBV DNA (>1×104 copies /mL or > 2000 IU/ mL); known hepatitis C virus infection (HCV) and HCV RNA positive (>1×103 copies /mL);

13. Any other medical condition, clinically significant metabolic abnormality, physical abnormality or laboratory abnormality, which, in the investigator's judgment, reasonably suspects that the patient has a medical condition or condition that is not suitable for the use of the investigational drug (such as having seizures and requiring treatment), or which would affect the interpretation of the study results or place the patient at high risk;

14. The patients considered by the investigators to be unsuitable for inclusion in this study.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Tianjin Medical University Cancer Institute and Hospital

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Ting Deng, MD

Role: PRINCIPAL_INVESTIGATOR

Tianjin Medical University Cancer Institute and Hospital

Locations

Tianjin Medical University Cancer Institute and Hospital

Tianjin, Tianjin Municipality, China

Site Status: RECRUITING

Countries

China

Central Contacts

Ting Deng, MD

Role: CONTACT

xymcdengting@126.com

022-23340123 ext. 1051

Jiayu Zhang, MD

Role: CONTACT

zhangjiayu152@163.com

15201752860

Facility Contacts

Ting Deng, MD

Role: primary

xymcdengting@126.com

022-23340123-1051

References

1. Sharma P, Hu-Lieskovan S, Wargo JA, et al. Primary, Adaptive, and Acquired Resistance toCancer Immunotherapy. Cell 2017; 168: 707-723. 2. Teng MW, Ngiow SF, Ribas A, et al. Classifying Cancers Based on T-cell Infiltration and PD-L1.Cancer Res 2015; 75: 2139-45. 3. Olson DJ, Eroglu Z, Brockstein B, et al. Pembrolizumab Plus Ipilimumab Following Anti-PD1/L1 Failure in Melanoma. J Clin Oncol 2021; 39: 2647-2655. 4. Pires da Silva I, Ahmed T, Reijers ILM, et al. Ipilimumab alone or ipilimumab plus anti-PD-1therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre,retrospective, cohort study. Lancet Oncol 2021; 22: 836-847. 5. Zaremba A, Eggermont AMM, Robert C, et al. The concepts of rechallenge and retreatmentwith immune checkpoint blockade in melanoma patients. Eur J Cancer 2021; 155: 268-280. 6. Yang K, Li J, Sun Z, et al. Retreatment with immune checkpoint inhibitors in solid tumors: asystematic review. Ther Adv Med Oncol 2020; 12: 1758835920975353. 7. Vera Aguilera J, Paludo J, McWilliams RR, et al. Chemo-immunotherapy combination afterPD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients. Melanoma Res2020; 30: 364-375. 8. Giaj Levra M, Cotte FE, Corre R, et al. Immunotherapy rechallenge after nivolumabtreatment in advanced non-small cell lung cancer in the real-world setting: A national data baseanalysis. Lung Cancer 2020; 140: 99-106. 9. Kitagawa S, Hakozaki T, Kitadai R, et al. Switching administration of anti-PD-1 and anti-PD-L1antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small celllung cancer: Case series and literature review. Thorac Cancer 2020; 11: 1927-1933. 10. Takahara Y, Tanaka T, Ishige Y, et al. Efficacy and predictors of rechallenge with immunecheckpoint inhibitors in non-small cell lung cancer. Thorac Cancer 2022; 13: 624-630. 11. Zhang Y, Wang ZX, Shen L, et al. A phase Ib/II study of fruquintinib in combination withpaclitaxel as the second-line therapy for advanced gastric cancer. Cancer Commun (Lond) 2023; 43:150-153.

Reference Type: RESULT

Other Identifiers

TJMUCH-GI-GC04

Identifier Type: -

Identifier Source: org_study_id